suPARnostic® provides improved risk stratification of patients in the emergency department.

Make better-informed clinical decisions

Using suPAR in clinical care allows healthcare professionals to identify and discharge more non-acute patients, reducing crowding, and healthcare costs. Earlier Identification of high-risk patients can provide faster clinical intervention and better patient outcomes.

suPARnostic® is the only CE-IVD certified product range applied for clinical measurement of suPAR in human plasma and serum. It enables healthcare professionals to make fast clinical decisions based on prognostic evidence across diseases.

A low suPAR level (under 4 ng/ml) indicates a good prognosis and supports the decision to discharge the patient.

A high suPAR level (over 6 ng/ml) indicates the presence, progression, and severity of disease, organ damage, mortality risk and supports further clinical attention.

Documented by 900+ peer-reviewed publications

Here you can find a summary of the research done on suPAR within different disease areas.

Drawing of People and a hospital bed

Achieve significant cost savings

In emergency departments and hospital wards, suPARnostic® can identify low-risk patients, resulting in earlier and safer discharges. A study examining the effectiveness of using suPAR as a risk stratification tool showed that hospitals could save one bed for 24 hours in every four patients admitted.1

“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”

MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen

Early anakinra treatment of COVID-19 patients guided by suPAR saves lives

Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.

1. Schultz et al. Disease Markers, 2019, 10;1-8A sub study of the interventional TRIAGE III trial, comparing patients with a valid suPAR measurement at admission to those without in EDs at two university hospitals in the Capital Region of Denmark.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research


Point-of-care finger prick

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates